Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00100321 | Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study | terminated | — | 25 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02465983 | Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | terminated | Phase 1 | 4 | University of PennsylvaniaOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01240304 | A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | University of ArkansasOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02166190 | RFA RCT for Pancreatic or Bile Duct Cancer(RFARCT) | terminated | N/A | 8 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02670746 | A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer(TRUST) | terminated | — | 44 | CelgeneINDUSTRY | 1 | Sep 16, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs | terminated | Early Phase 1 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | terminated | Phase 2 | 3 | Acerta Pharma BVINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | terminated | Phase 1 | 30 | The Cooper Health SystemOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | terminated | Phase 1 | 6 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT01314027 | Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer | terminated | Phase 3 | 38 | University of ZurichOTHER | 4 | Jul 25, 2019 | clinicaltrials |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy(PANCREADOGREL) | terminated | Phase 3 | 39 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | terminated | Phase 2 | 9 | CCTU- Cancer ThemeOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | terminated | Phase 2 | 2 | Augusta UniversityOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 8 | Eben RosenthalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT01276613 | Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas | terminated | Early Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02910882 | PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer(HALO-IST) | terminated | Phase 2 | 4 | Scripps HealthOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice(N1) | terminated | — | 23 | CureOneOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT02117479 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | terminated | Phase 3 | 321 | Incyte CorporationINDUSTRY | 12 | Mar 26, 2019 | clinicaltrials |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study | terminated | Phase 1 | 1 | University of ChicagoOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | terminated | Phase 2 | 17 | Beth Israel Medical CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | terminated | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01025882 | Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer | terminated | Phase 1 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02356640 | EUS-guided CGN for Inoperable Cancer | terminated | Phase 2 / Phase 3 | 3 | Chinese University of Hong KongOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02548169 | Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer(PancVax) | terminated | Phase 1 | 7 | Baylor Research InstituteOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00364364 | Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer. | terminated | Early Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01632306 | A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03225781 | Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer | terminated | N/A | 1 | Universita di VeronaOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT00310050 | Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | terminated | Phase 1 | 4 | Wake Forest University Health SciencesOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT00867126 | Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine | terminated | Early Phase 1 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 26, 2018 | clinicaltrials |
| NCT01086332 | Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer | terminated | Phase 1 | 7 | University of IowaOTHER | 0 | Nov 13, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00038701 | Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00276744 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | terminated | Phase 2 | 249 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT00868114 | Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer | terminated | Phase 2 | 24 | Leo W. Jenkins Cancer CenterOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT02204124 | Whipple Procedure: Standard of Care vs. Thunderbeat | terminated | N/A | 44 | Washington University School of MedicineOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02602067 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients(Tenatumomab) | terminated | Phase 1 | 2 | sigma-tau i.f.r. S.p.A.INDUSTRY | 2 | Sep 18, 2018 | clinicaltrials |
| NCT00783172 | Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer | terminated | Phase 1 | 4 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT01621243 | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 128 | Momenta Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT02241551 | Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 2 | Nathan Bahary, MDOTHER | 1 | Jul 26, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2019source: clinicaltrials